UK agency opens future of clinical trials to the public

By Jenni Spinner contact

- Last updated on GMT

(undrey/iStock via Getty Images Plus)
(undrey/iStock via Getty Images Plus)

Related tags: Uk, Mhra, Clinical trials, Regulation, Europe

The Medicines and Healthcare Products Regulatory Agency has released proposals to bolster trials legislation, asking citizens for input on the suggestions.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has opened up proposed clinical trials legislation launched for input from the public. The aim of the ambitious suggestions is to improve and strengthen the country’s clinical trials legislation, to make the country a better place to conduct research and develop safe, innovative treatments.

The eight-week consultation period is intended to collect public views on new proposals designed to improve government oversight and regulation of clinical trials. According to the agency, the aim of the legislation and public input solicitation is to “make the UK the leading global centre for innovative research design and delivery, across all types of trials​.”

Additionally, the effort to gather citizen feedback is to develop a system that better promotes the involvement of the public and potential patients, increases study inclusivity, streamlines clinical trial approvals, fosters innovation, and enhances trial transparency.

OSP_UKtrials_JR
June Raine, chief executive, Medicines and Healthcare Products Regulatory Agency

June Raine, MHRA chief executive, said, “This is a once-in-a-generation opportunity to review and update the UK legislation for clinical trials in order to make the UK the go-to place to develop new and innovative healthcare products.​”

The hopeful end result, according to MHRA representatives, is to deliver a streamlined, transparent, and flexible regulatory framework, all the while protecting patient participants that sign up for studies.

In addition to input from the public and patient participants, the MHRA also hopes to gather feedback from clinical research professionals, developers, manufacturers, sponsors, investigators, and healthcare industry members. The consultation period is open from January 17 to March 14, 2022; the agency reportedly will review all responses and use them to inform the finalized legislation.

The MHRA is responsible for regulating all medicines and medical devices in the UK. It is an executive agency of the UK’s Department of Health and Social Care.

For more information, read the full list of the consultation proposals and executive summary here.

Related news

Show more

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars